Background-Heart failure (HF) remains the most common reason for hospital admission in patients aged >65 years.
B
ecause of better treatment of acute myocardial infarctions and an aging society, the prevalence of chronic heart failure (HF) is continuously rising. 1 Despite advances in the management of chronic HF, it remains an increasing burden for patients and healthcare systems. More than half of the costs attributed directly to HF in the United States are related to in-hospital care 2 with HF hospital readmissions becoming increasingly frequent. 3, 4 By 2030, it is estimated that the direct cost of HF will reach 70 billion US$ up from 31 billion US$ in 2012. 5 
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Several reports indicate that hemodynamic changes precede the onset of symptoms of congestion by several days or even weeks. 6, 7 Currently available noninvasive screening methods to detect decompensation remain insensitive and do not reduce readmission rates. [7] [8] [9] [10] Thus, current standards are not sensitive enough to earlier identify patients at risk and to initiate therapy at an earlier stage. New outpatient remote monitoring and management tools could potentially offer better continuous functional assessments of prognostic parameters (eg, left ventricular [LV] end-diastolic pressure) versus traditional assessment. [11] [12] [13] [14] [15] Although miniaturized implantable leadless sensors for the direct assessment of LV performance that target the affected organ directly are presently missing in the diagnostic armamentarium and larger invasive devices and sensors placed in the pulmonary artery have been reported but can be confounded by changes in pulmonary vasculature. 7, 14 Two studies show the potential of hemodynamic monitoring in the patient with HF population: Ritzema et al 7 reported a pacemaker-like device to assess left atrial pressure. They demonstrated that by support through a physician-directed management system, they were able to improve left arterial pressure and reduce symptoms and early clinical events and costs. 16 , 17 Abraham et al 18 in the CHAMPION trial (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) demonstrated that a wireless implantable hemodynamic monitoring system that measures pulmonary artery pressure in New York Heart Association Remote Left Ventricular Hemodynamic Monitoring class III patients could help to reduce HF hospitalization rate when used to direct management of patients outside the hospital. 18 However, all currently available sensors have limitations, for example, they do not assess the LV performance directly or might detect false signals, for example, related to pulmonary conditions unrelated to the patient's underlying HF condition or cannot be used continuously. [19] [20] [21] Here, we report the first preclinical study using a newly developed leadless and batteryless LV-microelectromechanical system (MEMS) to assess relevant LV hemodynamic parameters directly.
Methods
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Ethics Statement
All study procedures complied with the current national legislation (German protection of animals act [ May 18, 2016] , last amended by article 4 paragraph 87 [BGBl. I S. 1666] on July 18, 2016, and the EU directives 63/2010 [on the protection of animals used for scientific purposes]). All performed study protocols were approved by the competent regional regulatory authority (LANUV NRW in Duesseldorf/Germany) and by the institutional animal care office of Bayer AG. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication no. 85-23, revised 1985) .
Sensor Design
For this study, a miniaturized sensor (LV-MEMS; St. Jude Medical) was developed for pressure detection based on microelectromechanical technology. The leadless and batteryless device is shown after implantation under fluoroscopy in Figure 1A . The dimensions of the cylindrical device are in total 13.9×1.6 mm 2 . The device is held in position via a small anchor coil that is screwed into the apex of the LV and visualized during catheterization. The anchor coil length is 3.0 mm and based on the corresponding anchors used in pacemaker probes. Because of the batteryless design, the life time is not limited. Displayed in Figure 1B are the monitor and the antenna to interrogate the sensor.
Pacemaker and LV-MEMS Implantation
For pacemaker-, LV-MEMS implantation and hemodynamic evaluation on day 0, 5 male beagle dogs (Marshall BioResources) weighting between 10 and 15 kg were anesthetized using pentobarbital (15-30 mg/kg to effect, Narcoren, Merial, Germany). For analgesia, fentanyl (10-40 µg/kg per hour, Mallinckrodt Inc) was infused through the right cephalic vein. During all experimental procedures, animals were intubated and mechanically ventilated with 30% oxygen using an Avance anesthesia ventilator (GE Healthcare, Germany). During sensor implantation and hemodynamic examination, the animals were protected from thromboembolic risk by using a loading dose of 200 U/kg heparin (B. Braun, Germany) followed by a continuously infusion of 20 U/kg per hour Heparin.
Under fluoroscopic guidance (OEC FlexiView 8800, GE Healthcare) and under aseptic conditions, a steroid-eluting pacemaker lead (Setrox S60, Biotronik, Germany) was inserted through an axillary vein into the right ventricle, anchored and connected to a pacemaker (Logos, Biotronik, Germany). To confirm the correct placement and capture threshold, the intracardiac signals were measured. The electronic device housing was placed subcutaneously between the shoulder blades.
Arterial and a second venous access point were secured by insertion of introducer sheaths (Terumo, Japan) in the right carotid artery and jugular vein by Seldinger technique. For LV pressure measurement, the newly developed LV-MEMS (St Jude Medical) was used. The LV-MEMS was fixed on the distal end of a custom push rod for loading and advancing the sensor. For sensor placement, an introducer guiding sheath (Model RSR01, Terumo) was used to access the LV from the carotid artery. Afterward, the custom push rod was inserted through the guiding catheter and advanced under fluoroscopic guidance until the anchor was positioned up against the cardiac tissue in the apex of the LV. The back end of the advancer was turned clockwise at least 3 full rotations to fix the sensor before retracting the catheter.
Study Protocol
The overall study protocol is illustrated in Figure 2A . Figure 2B shows the acute experimental examinations that took place on day 0, 21, and 35. Before sensor implantation, pentobarbital anesthetized animals were examined for cardiac or pulmonary abnormalities by invasive and echocardiographic examination. Afterward, the LV-MEMS prototype sensor and a right ventricular pacemaker were implanted by x-ray-guided catheter technique. Invasive LV pressure measurements were used as reference for calibration and to validate the LV-MEMS. Accuracy of device measurements during pharmacological interventions was tested using dobutamine and vasopressin challenges.
On the day of the pacemaker implantation (day 0), invasive hemodynamic measurements were performed to establish the baseline condition. After wound healing, the pacemaker was set to pacing mode (ie, pacing the right ventricle at a rate of 220 beats per minute [bpm]) on day 7 to induce HF. LV-MEMS measurements in conscious animals were performed through noninvasive data capture on a daily basis between day 1 and day 35. All readings were recorded under active pacing and during a brief phase of 3 minutes when the pacemaker was disabled to allow for measurement under spontaneous rhythm. The study ended on day 35 with euthanasia and necropsy.
Validation of Hemodynamic Measurements in Healthy Animals
After sensor implantation, the guiding catheter was replaced with Micro-Tip pressure catheters (Model SPR-350, Millar) for invasive left ventricular pressure measurement. Furthermore, for measurement of pulmonary artery pressure, central venous pressure and cardiac output right heart catheters (Model 631HF55, Edwards Lifesciences) were placed. Readings with the LV-MEMS were obtained by holding an antenna (Model CardioMEMS HF System, St. Jude Medical) to the thorax of the animals to capture noninvasive left ventricular pressure signals via radiofrequency technique. For all stages and time periods, LV pressures were averaged from 3 consecutive measurements
WHAT IS KNOWN
• Noninvasive screening methods are ridden by inaccuracy and insensitivity to early identify patients at risk for heart failure.
• Continuous hemodynamic monitoring can help to detect early signs of decompensation to initiate therapy at an earlier stage.
• Currently available sensors do not assess the left ventricular performance directly, or might detect false signals or cannot be used continuously.
• Here, we report the first preclinical study validating a new batteryless and easy to implant left ventricularmicroelectromechanical system.
WHAT THE STUDY ADDS
• Direct assessment of left ventricular pressure using microelectromechanical pressures sensors has the potential to become a future telemetric approach to guide the treatment of patients with heart failure. Remote Left Ventricular Hemodynamic Monitoring of 10-second recordings. Invasive left ventricular pressure measurements were used as reference for calibration and to validate the method during different drug applications. After hemodynamic stabilization, control measurements were performed. Afterward, a high dosage of 400 mU/kg vasopressin (AVP, Sigma Aldrich, V0377-50IU [Arg8]-Vasopressin) was given intravenously as a bolus injection to provoke functional cardiac depression. Hemodynamic measurements were performed 1, 2, 5, 10, 15, and 30 minutes post-application. To determine the myocardial inotropic reserve, dobutamine was given intravenously at doses of 1, 3, 5, and 10 µg/kg per minute. Invasive and telemetric data were collected every 5 minutes after infusion start for each dose. As third pharmacological intervention, a low dose of vasopressin (0.12, 0.4, 1.2, and 4 mU/kg per minute IV) was chosen. Data recordings were acquired 20 minutes after start of the infusion.
After acute testing, all catheters were removed. All animals received antibiotic (5 mg/kg Enrofloxacin PO [Baytril], Bayer/Germany) and Figure 1 . A, The left ventricular-microelectromechanical system (LV-MEMS) device, including the thread that is fixed in the apex of the left ventricle is measuring 13.9×1.6 mm 2 . The sensor is batteryless and is capable of measuring left ventricular pressures and various other hemodynamic parameters. The sensor is implanted during catheterization. Sensor position was visualized after implantation in the heart muscle. B, After implantation of the device, left ventricular pressure can be directly monitored using a remote antenna and monitor. 
Cardiac Hemodynamics in Conscious Animals and HF Induction
After wound healing, animals were studied in the awake state to evaluate cardiac pressure measurements. Between day 0 and day 7, daily measurements were performed before pacing. On day 7, pacemakers were activated (pacing mode [A00-Mode, current 3.6 V] with a frequency of 220 bpm), and pacing continued for 28 days to induce a chronic HF condition (from day 7 to day 35). During this pacing phase, all animals were investigated for their HF progression. Daily noninvasive pressure measurements were performed (3 consecutive recordings) during pacing and during spontaneous rhythm after short-time deactivation (at least 1 minute) of the pacemaker using the noninvasive CardioMEMS antenna and recording system (Model Interrogator 2, CardioMEMS HF System; St Jude Medical).
Hemodynamics in HF Dogs
After 14 and 28 days, paced dogs were studied again using the invasive diagnostic procedures as applied on day 0. Five healthy animals were studied in the same experimental protocol ( Figure 1B ). Pharmacological interventions using dobutamine were performed to illustrate the inotropic incompetence during HF conditions, and vasopressin was used to simulate a more pronounced cardiac depression.
Sensor Placement
Radiological evaluations were done on day 0, 21, and 35 to assess sensor positioning. Using application of contrast agent (Ultravist, Bayer, Germany) in the LV cavum via a LV catheter, muscle penetration by the LV-MEMS was excluded. After final hemodynamic investigations on day 35, all animals were euthanized, and visual cardiac examinations was performed to verify LV-MEMS positioning. Via tissue staining, the muscle surrounding the sensor was examined to characterize inflammatory or fibrotic reactions induced by the sensor.
HF Assessment by Biomarker and Echocardiography
For HF assessment, plasma samples were collected on day 0, 21, and 35. Brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide were determined using Cardiopet pro BNP Elisa test (IDEXX Laboratories, Germany) and Canine Brain Natriuretic Peptide Eliza test (Biotrend Chemikalien, Germany). Transthoracic 2-dimensional echocardiography was obtained (Vivid I, GE Healthcare) on day 0, 21, and 35 after initial anesthesia of animals as described above. Ejection fraction, LV systolic and diastolic volumes, and diameters were calculated from biplane 4-and 2-chamber views.
Data Acquisition, Flow, and Analysis
Wireless pressure readings were done by placing an antenna at the thorax of the animals using the noninvasive CardioMEMS antenna and recording system. Readings were transferred by an external hard disk to a computer and were analyzed by Ponemah software (version 5.2, Data Sciences International) to calculate heart rate, LV systolic and end diastolic pressures, contractility, and relaxation from the LV pressure signal. All invasive data were recorded by Ponemah software and were analyzed in the same way as telemetric data.
Statistical Analysis
The statistical analysis and creation of graphics were done using GraphPad Prism software (version 6.07, GraphPad Software Inc). All data were expressed as mean±SEM or SD (Table) . Group differences between invasive and telemetric measurements were analyzed by Wilcoxon-matched pairs signed-rank test. Repeated measurement 1-way ANOVA followed by Dunnett multiple comparisons test was used to analyze the data in view of statistical significance of pharmacological interventions and experimental induced disease conditions. An α-level of <0.05 was used for all analysis.
Results

Device Characterization
The goal of this study was to test the functionality and feasibility of a new cardiac monitoring device (LV-MEMS) for telemonitoring of HF. In general, the placement and usage of the sensor was well tolerated, and specifically no dislocation Data are expressed as mean of n=5±SD. BNP indicates brain natriuretic peptide; BW, body weight; CO, cardiac output; CVP, central venous pressure; EF, ejection fraction; HR, heart rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEDV A2C, left ventricular end-diastolic volume measured in 2-chamber view; LVEDV A4C, left ventricular end-diastolic volume measured in 4-chamber view; LVESV A2C, left ventricular end-systolic volume measured in 2-chamber view; LVESV A4C, left ventricular end-systolic volume measured in 4-chamber view; LVLd A2C, left ventricular length at diastole measured in 2-chamber view; LVLd A4C, left ventricular length at diastole measured in 4-chamber view; LVLs A2C, left ventricular length at systole measured in 2-chamber view; LVLs A4C, left ventricular length at systole measured in 4-chamber view; MBP, mean blood pressure; mPAP, mean pulmonary artery pressure; and PCWP, pulmonary capillary wedge pressure. 
Canine HF Model
The different hemodynamic and echocardiographic readouts as well as the results of biomarker measurements are summarized in the Table. The parameters indicate that the paced dogs developed an HF phenotype characterized by increased filling pressures, enlarged chamber diameters, and elevated biomarker levels. Furthermore, the ejection fraction dropped by 27% compared with the prepacing period as shown by echocardiography. Furthermore, the evolving HF state was reflected by a rising N-terminal pro-B-type natriuretic peptide concentration from initially 277±39.8 to 3280±1287.1 pmol/L.
Telemetric Readings of LV Function in Conscious Animals
The data that are shown in Figure 3 were collected using the LV-MEMS. The heart rate was used as a control to ensure successful ventricular capture and pacing, respectively ( Figure 3A) . Also, the increasing spontaneous resting heart rate during the course of the study because of the development of HF is depicted in Figure 3A . The heart rate increased by 38% from an initial rate of 116±16 to 163±27 bpm (HF state). In the same course, the LV systolic pressure dropped by 30% ( Figure 3B ) from initially 158±15 to 111±10 mm Hg (end of the study). LV end-diastolic pressure, a central marker in HF, rose continuously during our study ( Figure 3C ) from 12±5 to 24±7 mm Hg. Furthermore, there was a significant drop in contractility (59%), relaxation (59%), and an increase in the time constant of relaxation ( Figure 3D-3F ). Taken together, these results indicate mildly congestive state in this canine model of HF.
Comparison Between Millar-Catheter and LV-MEMS Device
The LV-MEMS device was compared with an invasive catheter (Millar-catheter) on day 0 (healthy animals), 21 Figure 4C ). Furthermore, pulmonary capillary wedge pressure (Table) , LV end-diastolic pressure ( Figure 4C ), and mean pulmonary artery pressure (Table) were compared: pulmonary capillary wedge pressure and LV end-diastolic pressure but not mean pulmonary artery pressure showed a significant increase after 14 and 28 days of ventricular pacing without significant differences between Millar-catheter and LV-MEMS device. For contractility, relaxation, and time constant of relaxation, again no significant differences Figure 4D-4F ) in the healthy as well as HF states. An increase in dP/dt in the healthy and diseased states in our protocol using the different pharmacological interventions is shown in Figure 4G -4I with similar precision of LV-MEMS versus Millar-catheter ( Figure I in the Data Supplement). Between the different time points, the effect of dobutamine decreased, which is caused by inotropic incompetence during HF development. Figure 5 shows the Bland-Altman Plots that summarize the comparison of the prototype LV-MEMS with the gold standard (Millar-catheter) under baseline and pharmacological challenge conditions in healthy and diseased animals. The LV-MEMS was equally sensitive in detecting hemodynamic changes based on pharmacological interventions by dobutamine or vasopressin (shown in 4, 6; Figure I in the Data Supplement). Overall, accordance between the LV-MEMS and the current gold standard of left heart catheter measurement techniques was observed over a wide range of different conditions.
Discussion
This is the first study demonstrating the feasibility and accuracy of a wireless LV pressure measurement using a newly developed LV-MEMS device during HF conditions. Wireless monitoring of an implanted pressure sensor could have the potential to improve the standard of care for management of chronic diseases where pressure is an important factor. Improved management of HF outside the hospital has been the focus of previously randomized trials. The COMPASS-HF trial (Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure) enrolled 274 New York Heart Association classes III and IV HF patients.
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A sensor was placed in the right ventricular outflow tract for a period of 6 month. The study showed a 21% reduction in the rate of HF-related events at 6 months that was not statistically significant (P=0.33). The CHAMPION trial enrolled 550 New York Heart Association class III HF patients using the CardioMEMS HF System (St. Jude Medical, Inc) placed into the pulmonary artery. There was a 28% reduction in HF hospitalizations observed after 6 months (P=0.0002) which increased to a 37% reduction over the total timeframe of 15 months. These results led to the Food and Drug Administration approval of the CardioMEMS HF System. 18 Our study indicates that the newly developed leadless LV-MEMS allows for continuous LV hemodynamic performance monitoring in an animal model of HF. The performance characteristics match those of the current gold standard. The LV-MEMS ( Figure 1A ) has several potential advantages over established approaches with implant placement in the right heart or pulmonary artery because the parameters measured allow direct assessment of LV function. This could offer additional benefits in the early detection of cardiac hemodynamic changes (pulmonary artery pressure rises later than LV pressure during acute HF impairment) and may be more specifically diagnostic of LV dysfunction (pulmonary artery pressure may be confounded by other conditions, eg, pulmonary diseases).
The biomarker and echocardiography data in the Table showed that the pacing-induced canine model of HF was characterized by a depression of LV function sustained on cessation of pacing. The progression that was recorded after the induction of HF was captured by the LV-MEMS (Figure 3) . Also in comparison with a left heart catheterthe clinical gold standard-no differences were observed (Figure 4) . Because of the characteristics of our LV-MEMS, the data could easily be shared between the patient and the physician allowing new treatment strategies. To test this hypothesis, we included the use of a pharmacological intervention by dobutamine and vasopressin in our study protocol (Figures 4-6) . The physiological effect of the pharmacological challenge was visible with the hemodynamic data provided by the MEMS device. Vasopressin and dobutamine challenges were used as pharmacological challenges to investigate hemodynamic changes in this model. The summarized experiments in Figure 5 indicate that the LV-MEMS can reliably detect introduced hemodynamic changes. A limitation of the present study is the use of the LV-MEMS device in a relatively small number of animals and the relevance of the applied animal model; however, the rapid pacing model of HF used in this study is extensively described in literature and reflects major aspects of the human disease phenotype, as previous research has shown. [22] [23] [24] The current study aimed at investigating the general functionality and feasibility of the LV-MEMS by direct comparison with standard invasive LV pressure recordings. The sample size and study design limit any conclusion on long-term safety aspects (dislocation of probe, thrombosis risks) or rare complications. The low interindividual variability observed in this study and similar studies reported in the literature, however, allowed us to extrapolate several interesting features of this model.
Moving on to a clinical trial, the benefit-risk ratio has to be considered on the implantation of the sensor. First conclusions can already be drawn from the implantation of leadless pacemakers. The LEADLESS study (Nanostim Study for a Leadless Cardiac Pacemaker System) followed patients for 1 year, and no significant side effects were reported. However, safety concerns, including the risk for ventricular arrhythmias and sensor dislocation (eg, in patients with thin myocardial wall because of ischemic events or infarction), warrant additional attention. 25, 26 Implantation in a patient who might become a candidate for mechanical assist devices would also need further evaluation: Given the mechanical stress a left ventricular assist device could apply on the ventricle, limitations with respect to the attachment of the device might occur. In addition, the LV-MEMS needs to be tested with a longer follow-up period and different model of LV impairment-for example, ischemia versus rapid pacing-to demonstrate safety and functional characteristics with chronic use. 27 Furthermore, certain conditions, like thinned myocardium after ischemia, presence of assist devices, or pacemaker leads, would necessitate added in-depth validation and safety considerations. Also, a clinical protocol for anticoagulation and thrombus formation protection needs to be developed. Based on trials using left atrial appendage closure, the protocol could consist of heparin during the procedure and warfarin for an intermediate time that is later substituted with dual antiplatelet therapy. 28 In the end, if the sensor is fully endothelialized, a prevention only consisting of aspirin might be sufficient, which needs to be shown. Taken together, our preclinical results indicate that the newly developed LV-MEMS shows good functionality and feasibility. It has the potential to become a future telemetric tool to guide the treatment of patients with HF.
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